Longevity.Technology UNLOCKED

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health.

• Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.
• Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.
• Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.
• Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.
• Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing.

----------

News & References:

• Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/
• Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/
• Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/
• Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/
• Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

Guests:

Aaron Deere

Health and Performance Director of HOOKE London

LinkedIn: www.linkedin.com/in/aaron-deere-129079128/

Website: www.hooke.london/

Dr Jean-Marc Sobczyk

Integrative Medicine & Longevity Physician of HOOKE London

LinkedIn: www.linkedin.com/in/jean-marc-sobczyk/

Website: www.hooke.london/

----------

What if the future of longevity isn't about taking more supplements, but taking fewer, better ones?

In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare.

Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time.

The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention.

Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice.

In this episode, you’ll learn:

• Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.
• How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation.
• Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice.
• How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change.
• Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends.

Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine.

Subscribe for weekly episodes exploring longevity science, precision medicine, preventative healthcare, and the innovations shaping how we live longer, healthier lives.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy.

• BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.
• Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.
• Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.
• Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.
• Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.
• US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine.

----------

News & References:

• BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/
• Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/
• Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/
• When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/
• Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/
• US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

Guests: Professor Ronjon Nag, OBE

President of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRoots

LinkedIn: www.linkedin.com/in/ronjonnag/

Website: www.r42group.com/, agemica.com, app.superbio.ai, genomelink.io, yourroots.com

----------

What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan?

Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare.

Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways.

The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare.

Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease.

In this episode, you’ll learn:

• Why most diseases are influenced by thousands of genes, not just one
• How AI is making genetics more useful for everyday healthcare
• Why combining genetics with biomarkers creates better health insights
• How preventative medicine is moving toward personalized risk prediction
• The science behind peptide vaccines targeting aging pathways
• Why AI may soon let you "talk" to your own biology

If you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan.

Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine mRNA plaque reversal, affordable longevity clinics, laser-driven skin rejuvenation, immune rejuvenation, cuffless blood pressure monitoring, and peptide evidence.

• Repair Biotechnologies received FDA pathway eligibility for its investigational mRNA therapy targeting intracellular cholesterol, a novel approach that aims to reverse arterial plaque rather than simply lower LDL or slow cardiovascular disease progression.
• Fountain Life launched a new $595 annual membership, signaling a strategic shift beyond luxury longevity medicine toward employer benefits, insurance integration, and broader access to advanced preventive care.
• Researchers from Nature’s Scientific Reports has found that Candela’s Nordlys fractional laser treatment produced sustained epigenetic changes associated with younger skin biology, raising the possibility that aesthetic procedures could influence the biology of aging rather than just appearance.
• United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in thymus regeneration, immune rejuvenation, and the commercial potential of therapies targeting age-related immune decline.
• Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, that has entered a large Korean cohort study, potentially making continuous cardiovascular monitoring more practical than traditional inflatable cuffs.
• Evipedia launched transparent, AI-supported evidence reviews covering 24 peptides, providing clinicians and consumers with an up-to-date resource as regulators continue scrutinizing peptide safety, efficacy, and clinical evidence.

----------

News & References:

• Repair Bio advances plaque regression program with FDA nod → https://longevity.technology/news/repair-bio-advances-plaque-regression-program-with-fda-nod/
• Fountain Life makes longevity accessible with $595 membership → https://longevity.technology/news/fountain-life-makes-longevity-accessible-with-595-membership/
• Laser treatment found to reverse skin aging markers → https://longevity.technology/news/laser-treatment-found-to-reverse-skin-aging-markers/
• United Therapeutics buys Thymmune Therapeutics for $140m → https://longevity.technology/news/united-therapeutics-buys-thymmune-therapeutics-for-140m/
• Evipedia expands evidence reviews to cover peptides → https://longevity.technology/news/evipedia-expands-evidence-reviews-to-cover-peptides/
• Sky Labs’ blood pressure ring adopted for large-scale national health study → https://longevity.technology/news/sky-labs-blood-pressure-ring-adopted-for-large-scale-national-health-study/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Viome

Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and nutrition. By identifying what's happening inside your body in real time, Viome delivers tailored food, supplement, and lifestyle recommendations designed to support your long-term health and wellness journey.

Click the link below to learn more.

Link: viomehq.sjv.io/BX74XL

----------

Guests: Naveen Jain

Founder and CEO at Viome Life Sciences

Instagram: www.instagram.com/naveenjainceo/?hl=en

Website: www.viomelifesciences.com/

----------

What if the biggest breakthrough in longevity isn't changing your DNA, but understanding what your genes are doing right now?

Phil Newman and Dr. Nina Patrick sit down with Naveen Jain, entrepreneur, innovator, and founder of Viome, to explore why RNA biology, AI, and the microbiome are reshaping the future of preventative healthcare. While DNA tells us what is possible, Jain argues that RNA reveals what is actually happening inside the body in real time, creating opportunities to detect dysfunction years before symptoms appear.

From analyzing more than 400 quadrillion biological data points across 1.5 million biological samples to using AI to interpret millions of microbial and human gene expression signals, the conversation explores how precision diagnostics are moving beyond traditional blood testing. Jain explains why two people can eat the same foods and experience completely different biological outcomes, why there may be no such thing as a universally healthy food, and how personalized nutrition could become one of the most powerful tools for extending healthspan.

The discussion also examines the rise of longevity medicine, the consumerization of healthcare, the growing role of AI in clinical decision making, and why early disease detection may become one of the defining advances of this decade. Jain shares how Viome is developing RNA-based diagnostics for conditions including oral cancer, pancreatic cancer, inflammatory bowel disease, and metabolic dysfunction, while also discussing the importance of scientific validation and evidence-based recommendations.

In this episode, you’ll learn:

• How AI can interpret millions of biological signals that humans cannot analyze manually.
• Why personalized nutrition may outperform generalized dietary advice.
• How the microbiome influences inflammation, metabolism, cognition, and biological aging.
• Why foods like broccoli, spinach, avocado, almonds, and red meat can produce very different effects depending on your biology.
• How Viome's research is advancing early detection for pancreatic cancer, oral cancer, and metabolic disease.

If you want to understand how AI, molecular biology, and the microbiome are changing the future of preventative medicine, this episode connects cutting-edge science with practical insights for extending healthspan and longevity.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the innovations shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR heart therapies, AI-guided Alzheimer's care, GLP-1 ecosystem expansion, biological age testing, Klotho programs, and regenerative medicine.

• Scribe Therapeutics secured more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance two CRISPR-based gene editing therapies toward human trials. The one-time treatments, STX-1200 and STX-1400, target inherited cardiovascular risk factors with the goal of durably reducing genetically driven heart disease risk.
• Eli Lilly's LillyDirect and ŌURA announced a collaboration to support people using prescribed GLP-1 therapies by combining access to treatment with wearable-based behavioral support. The initiative integrates sleep, activity, readiness, and other biometric insights to help reinforce healthy habits alongside obesity care, without sharing user data between the companies.
• NeuroXT and Beth Israel Deaconess Medical Center (BIDMC) expanded their collaboration to explore how AI could help identify the right treatment for the right Alzheimer’s patient. The research aims to identify which patients are most likely to benefit from emerging Alzheimer's therapies using imaging that is already widely available.
• Generation Lab launched SystemAge 2.1, describing it as the first biological age test to offer dedicated female and male versions. The platform analyzes more than 460 biomarkers across 21 organ systems from a needle-free blood sample, adding sex-specific assessments and organ-level tracking to monitor responses to longevity interventions.
• GARM Clinic debuted what it describes as the world's first Klotho Longevity Residency, a four-day educational program focused on Klotho-based gene therapy and regenerative medicine. Hosted in Roatán, Honduras, the residency brings together clinicians and researchers to explore translational longevity therapies in a more flexible regulatory setting.
• LyGenesis received a research award to expand its regenerative medicine platform into type 1 diabetes, to support a thymus program exploring immune tolerance to pancreatic islet transplantation. The funding will support preclinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation for type 1 diabetes, according to the company.

----------

News & References:

• Scribe lands $25m to advance heart disease gene therapies → https://longevity.technology/news/scribe-lands-25m-to-advance-heart-disease-gene-therapies/
• ŌURA-LillyDirect collab highlights new GLP-1 care model → https://longevity.technology/news/oura-lillydirect-collab-highlights-new-glp-1-care-model/
• AI and Alzheimer’s: NeuroXT, BIDMC aim to personalize care → https://longevity.technology/news/ai-and-alzheimers-neuroxt-bidmc-aim-to-personalize-care/
• Generation Lab launches SystemAge 2.1 as the first gender-specific biological age test → https://longevity.technology/news/generation-lab-launches-systemage-2-1-as-the-first-gender-specific-biological-age-test/
• GARM Clinic debuts world’s first Klotho longevity residency → https://longevity.technology/news/garm-clinic-debuts-worlds-first-klotho-longevity-residency/
• LyGenesis wins research award to advance type 1 diabetes cell therapy → https://longevity.technology/news/lygenesis-wins-research-award-to-advance-type-1-diabetes-cell-therapy/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: fatty15.com/UNLOCKED

----------

Guests:

Stephanie Venn-Watson, DVM, MPH

Co-Founder, Chief Executive Officer, Fatty15

LinkedIn: www.linkedin.com/in/stephanievennwatson/

Website: fatty15.com/

Nicholas J. Schork, PhD, MA

Co-Founder, Senior Sciencist, Fatty15

Research: www.researchgate.net/profile/Nicholas-Schork

Website: fatty15.com/

----------

What if one of the most influential nutrition recommendations of the last 50 years overlooked a nutrient essential for long-term health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Stephanie Venn-Watson, veterinary epidemiologist, public health scientist, inventor, and co-founder of Fatty15, alongside Dr. Nicholas Schork, distinguished professor and leading researcher in quantitative medicine and longevity science, to explore the emerging evidence behind C15 and the future of nutrition research.

Together they examine how dietary guidelines introduced in 1977 led to widespread reductions in saturated fat consumption, while rates of obesity, metabolic disease, fatty liver disease, and type 2 diabetes continued to climb. Drawing on evidence from population studies, molecular biology, and animal research, they discuss why not all saturated fats behave the same way and how advances in metabolomics are helping researchers identify specific nutrients that may play critical roles in health and aging.

The conversation traces the remarkable discovery of C15 from aging Navy dolphins, where researchers found that higher C15 levels were associated with healthier aging and lower rates of metabolic dysfunction. They explore why C15 is emerging as a candidate essential fatty acid, how it may support cell membrane stability, mitochondrial function, AMPK activation, inflammation regulation, and metabolic resilience, and why some researchers now view it as a promising geroprotector.

They also discuss childhood nutrition, dairy consumption trends, grass-fed dairy, personalized versus essential nutrition, anemia, metabolic disease, and the challenges of translating emerging science into public health recommendations.

In this episode, you’ll learn:

• Why researchers believe saturated fats should no longer be treated as a single category
• How Navy dolphin research led to the discovery of C15's potential health benefits
• Why every 0.1% increase in circulating C15 has been associated with a 32% lower risk of developing type 2 diabetes
• What makes C15 a potential geroprotector that may influence multiple hallmarks of aging- How future dietary guidelines may evolve as evidence around C15 continues to grow

If you want to understand how advances in nutrition science, aging biology, and public health research are reshaping our understanding of dietary fat, this episode offers a thought-provoking look at one of the most debated topics in longevity today.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR gene editing, national longevity strategies, AI-powered drug discovery, next-generation health imaging, metabolic therapies, and the impact of forever chemicals on aging.

• Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a one-time in vivo CRISPR treatment for hereditary angioedema. Patients saw an 87% reduction in monthly attacks, marking the first successful pivotal Phase 3 trial of an in vivo CRISPR gene-editing therapy.
• Canada's "Shaping Canada's Longevity Advantage" initiative, backed by Manulife and the World Economic Forum, aims to improve health, financial resilience, and social connectedness for one million Canadians within three to five years.
• Insilico Medicine signed a collaboration with SK Biopharmaceuticals worth more than $2.5 billion in potential milestone payments. The partnership will use Insilico's Pharma.AI platform to develop therapies for neuroimmune and central nervous system disorders.
• Midjourney unveiled plans for Midjourney Medical, a full-body imaging platform designed to create detailed body maps in approximately 60 seconds. The company plans to launch its first scanning facility in San Francisco in 2027.
• Cambrian Bio presented Phase 1B data for ATX-304 in adults with obesity and prediabetes. After eight weeks, participants showed an 8% increase in resting metabolic rate alongside reductions in visceral fat, liver fat, and triglycerides.
• New research linked common PFAS "forever chemicals" to accelerated epigenetic aging. The findings highlight how environmental exposures may influence biological age and why longevity strategies may need to address toxic burden alongside lifestyle interventions.

----------

News & References:

• World’s first in vivo gene editing Phase 3 win → https://longevity.technology/news/worlds-first-in-vivo-gene-editing-phase-3-win/
• Building Canada’s longevity advantage → https://longevity.technology/news/building-canadas-longevity-advantage/
• Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure → https://longevity.technology/news/insilicos-2-5b-ai-drug-discovery-deal-targets-neuroimmune-failure/
• New image? AI art giant Midjourney’s wildest leap into longevity → https://longevity.technology/news/new-image-ai-art-giant-midjourneys-wildest-leap-into-longevity/
• Human data validate Cambrian Bio’s aging target → https://longevity.technology/news/human-data-validate-cambrian-bios-aging-target/
• Forever chemicals may be aging you – longevity needs to wake up → https://longevity.technology/news/forever-chemicals-may-be-aging-you-longevity-needs-to-wake-up/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

Guest: Wei-Wu He

Chairman and CEO, Human Longevity, Inc.

LinkedIn: www.linkedin.com/in/wei-wu-he-ph-d-he-him-b6957313/

Website: www.humanlongevity.com/

----------

What if the future of medicine isn't about treating disease, but predicting it years before symptoms ever appear?

Phil Newman and Dr. Nina Patrick sit down with Dr. Wei-Wu He, CEO and Executive Chairman of Human Longevity Inc. (HLI), to explore how genomics, AI, multiomics, and precision medicine are converging to create an entirely new model of healthcare. A longtime entrepreneur, investor, and advocate for longevity science, Wei-Wu shares how HLI has evolved from one of the world's most ambitious genomics projects into a global precision health platform focused on disease prevention, risk prediction, and personalized intervention.

The conversation explores why genome sequencing may become one of the most important medical tools of the next decade, and why Dr. He believes every person should have access to their genomic data. He explains how advances in AI are making it possible to interpret vast amounts of biological information, turning genome sequences, imaging scans, blood biomarkers, and longitudinal health records into actionable insights that can guide both patients and physicians.

Wei-Wu also discusses HLI's collaboration with Insilico Medicine to build AI-powered foundation models for longevity and disease prediction, the importance of diverse global datasets, and why population-specific genomic algorithms may outperform one-size-fits-all approaches developed from Western biobanks alone.

The discussion expands beyond technology to explore the broader future of healthcare. Why are countries like China, the UAE, and Singapore moving aggressively into genomic medicine? What role will governments, insurers, and healthcare systems play in making prevention more accessible? And how close are we to a world where AI-powered health guidance becomes a routine part of everyday medical care?

In this episode, you’ll learn:

• Why recent research suggests genetics may account for roughly 50% of lifespan variation
• How whole genome sequencing is becoming dramatically more affordable and accessible
• Why AI may outperform human experts in specific diagnostic tasks
• Why pancreatic cancer outcomes depend heavily on stage-zero and stage-one detection
• Why China, the UAE, and other countries are investing heavily in genomic healthcare
• How longevity clinics may evolve into mainstream healthcare over the coming decade

If you want to understand how AI, genomics, and longitudinal health data may transform medicine, this episode connects cutting-edge science with practical strategies for extending healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.